Remove

Remove

Τ۶

Pages,Columns,Lines where

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Not for submission under 37 CFR 1.99)

	Application Number Filing Date		10802509
			2004-03-17
	First Named Inventor Morte		n Middelfart
	Art Unit		2177
	Examiner Name Nath:		in Hillery
	Attorney Docket Number		1032927-000071

Initial*	No	Pater	nt Number	Code <sup>1</sup>	Issue Da	ite	of cited Docu	ment		vant Passages or Relev es Appear	ant
	1	76675	682	B1	2010-02-2	23	Waldorf				
If you wis	h to ad	ld additi	onal U.S. Pater	t citatio	n informal	tion pl	ease click the	Add button.		Add	
				U.S.P.	ATENT A	PPLK	CATION PUBL	ICATIONS		Remove	
		Name of Pate of cited Docu	intee or Applicant ment	Rele	s,Columns,Lines where vant Passages or Relev es Appear						
	1	200	70294612	A1	2007-12-2	20	Drucker et al.				
If you wisl	h to ad	d additi	onal U.S. Publis	shed Ap	plication of	citation	information p	lease click the Ad	d butto	n. Add	
					FOREIGI	N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*		Foreigi Numbe	n Document	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	та
	1										
If you wish	h to ad	ld addit	onal Foreign Pa	atent Do	cument ci	itation	information pl	ease click the Add	butto	n Add	_

NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

publisher, city and/or country where published.

(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s),

U.S. PATENTS

Examiner Cite

Initials\* No

	Application Number		10802509		
	Filing Date		2004-03-17		
	First Named Inventor	Morte	forten Middelfart		
STATEMENT BY APPLICANT  Not for submission under 37 CFR 1.99)	Art Unit		2177		
(Not for Submission under or or it 1.50)	Examiner Name	Nathan Hillery			
	Attorney Docket Number		1032927-000071		

1	Office Action issued in related U.S. Patent App. No. 12/112,178 dated January 4, 2012.	×

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See first Gode of USPTO Patent Documents at times USETO.GGU or MPEP 961.04. 2 lister of finis that issued the document, by the two-lets of (MPC) Standard ST3.) - 15 reparases patent documents, the orbidates of the parent for many precedes the sealth content to plant document. A standard ST3.0 - 15 reparases patent document, the orbidates of the parent for many precedes the sealth content. A plant document with the parent document to the parent for sealth or the parent for sealth or the parent for sealth or 15 reparts and the parent parent for the parent for sealth or 15 reparts and the parent parent for the parent for sealth or 15 reparts and the parent parent for the parent for sealth or 15 reparent for sealth

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10802509		
Filing Date		2004-03-17		
First Named Inventor	Morte	n Middelfart		
Art Unit		2177		
Examiner Name	Natha	n Hillery		
Attorney Docket Numb	er	1032927-000071		

#### CERTIFICATION STATEMENT

Please see 37	7 CFR 1.97	and 1.98 to	make the appro	priate selection(s	3):
---------------	------------	-------------	----------------	--------------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a design patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to item of information (and individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) and the contraction of the contraction of

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

# SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/James A. LaBarre/	Date (YYYY-MM-DD)	2012-01-13					
Name/Print	James A. LaBarre	Registration Number	28632					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1450, Alexandrin, V.S. 2311-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1450, Alexandria, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursyant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
  the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
  may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
  an application which became abandoned or in which the proceedings were terminated and which application is
  referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.